RSLS: 3,5199 +32,83%
52w: 2.49 - 61.45
SAN CLEMENTE, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 16/792,094, entitled, “Systems and Methods for Determining Failure of Intragastric Devices,” related to its Obalon® Balloon System. The patent will cover additional claims for the Obalon® Balloon System and is expected to provide protection into at least January 2031, without accounting for a potential Patent Term Extension (PTE).
“Allowance of this patent significantly strengthens our intellectual property portfolio around innovations for the Obalon Intragastric Balloon System,” stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences. “Since filing our first patent application in 2011, ReShape has pioneered the field, amassing a patent family around the intragastric balloon system, supported by a variety of novel, pending and protected inventions. Going forward, we will continue to build a defensive ‘moat’ around our product portfolio and commercialization efforts, while also taking offensive action to defend our patent position, when necessary.”
About ReShape Lifesciences™
ReShape Lifesciences® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. ReShapeCare™ is a virtual weight-management program that supports lifestyle changes for all weight loss patients led by board-certified health coaches to help them keep the weight off over time. The recently launched ReShape Marketplace™ is an online collection of quality wellness products curated for all consumers to help them achieve their health goals. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of Type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.
